The thirteenth international childhood acute lymphoblastic leukemia workshop report: La Jolla, CA, USA, December 7-9, 2011

Pediatric Blood and Cancer

Volumn 60, Issue 2, 2013, Pages 344-348

  Hunger, Stephen P ^a,b,c   Baruchel, Andre ^d,e   Biondi, Andrea ^f   Evans, William E ^g,h   Jeha, Sima ^h   Loh, Mignon ^c,h   Moericke, Anja ^i,j   Pieters, Rob ^k,l   Relling, Mary V ^g,h   Schmiegelow, Kjeld ^m,n   Schrappe, Martin ^i,j   Silverman, Lewis B ^o   Stanulla, Martin ^j,p   Valsecchi, Maria Grazia ^f   Vora, Ajay ^q,r   Pui, Ching Hon ^h  

^a Children's Hospital Colorado   (United States)

^b CHILDREN S HOSPITAL COLORADO   (United States)

^c Gynecologic Oncology Group   (United States)

^d HÔPITAL ROBERT DEBRÉ   (France)

^e French Acute Lymphoblastic Leukemia Study Group   (France)

^f UNIVERSITY OF MILANO BICOCCA   (Italy)

^g Associazione Italiana de Ematologica ed Oncologia Pediatrica   (Italy)

^h UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j Berlin Frankfurt Miu nster Group Germany   (Germany)

^k SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^l DUTCH CHILDHOOD ONCOLOGY GROUP   (Netherlands)

^m Rigshospitalet   (Denmark)

ⁿ Nordic Society of Pediatric Hematology and Oncology   (Denmark)

^o BOSTON CHILDREN S HOSPITAL   (United States)

^p HANNOVER MEDICAL SCHOOL   (Germany)

^q SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^r UNIVERSITY OF BIRMINGHAM   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; DASATINIB; DEXAMETHASONE; IMATINIB; JANUS KINASE; MIXED LINEAGE LEUKEMIA PROTEIN; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; TRANSCRIPTION FACTOR 7 LIKE 1; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR NKX2.2; TRANSCRIPTION FACTOR PBX1; TRANSCRIPTION FACTOR RUNX1; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RISK; CHILD; CHILDHOOD LEUKEMIA; CLINICAL TRIAL (TOPIC); DRUG MEGADOSE; EVENT FREE SURVIVAL; GENE FREQUENCY; GENE FUSION; GENE TRANSLOCATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HISTONE MODIFICATION; HUMAN; HYPERSENSITIVITY; LOSS OF FUNCTION MUTATION; MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; PANCREATITIS; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRE T LYMPHOCYTE; PRIORITY JOURNAL; SALVAGE THERAPY; SAMPLE SIZE; SKULL IRRADIATION; STEM CELL TRANSPLANTATION; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; WORKSHOP;

HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84871145966     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24354     Document Type: Article

References (64)

1. Arico M, Schrappe M, Hunger SP, et al. Clinical outcome of children with newly diagnosed philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol 2010; 28: 4755-4761.
2. Schrappe M, Hunger SP, Pui CH, et al. Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med 2012; 366: 1371-1381.
3. Trevino LR, Yang W, French D, et al. Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet 2009; 41: 1001-1005.
4. Orsi L, Rudant J, Bonaventure A, et al. Genetic polymorphisms and childhood acute lymphoblastic leukemia: GWAS of the escale study (SFCE). Leukemia 2012. DOI: 10.1038/leu.2012.148 [Epub ahead of print].
5. Yang JJ, Cheng C, Yang W, et al. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 2009; 301: 393-403.
6. Kawedia JD, Kaste SC, Pei D, et al. Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood 2011; 117: 2340-2347;
7. Ellinghaus E, Stanulla M, Richter G, et al. Identification of germline susceptibility loci in ETV6-RUNX1-rearranged childhood acute lymphoblastic leukemia. Leukemia 26: 902-909.
8. Chen SH, Pei D, Yang W, et al. Genetic variations in gria1 on chromosome 5q33 related to asparaginase hypersensitivity. Clin Pharmacol Ther 2010; 88: 191-196.
9. Spencer CC, Su Z, Donnelly P, et al. Designing genome-wide association studies: Sample size, power, imputation, and the choice of genotyping chip. PLoS Genet 2009; 5: e1000477.
10. Pui CH, Pei D, Sandlund JT, et al. Long-term results of st jude total therapy studies 11, 12, 13a, 13b, and 14 for childhood acute lymphoblastic leukemia. Leukemia 2010; 24: 371-382.
11. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009; 360: 2730-2741.
12. Pui CH, Campana D, Sandlund JT, et al. Treatment of childhood acute lymphoblastic leukemia without cranial irradiation. Ann Hematol 2011; 90: (Suppl. 1): S61-S63.
13. Hunger SP. Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: Clinical features and molecular pathogenesis. Blood 1996; 87: 1211-1224.
14. Jeha S, Pei D, Raimondi SC, et al. Increased risk for cns relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1. Leukemia 2009; 23: 1406-1409.
15. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in philadelphia chromosome-positive acute lymphoblastic leukemia: A children's oncology group study. J Clin Oncol 2009; 27: 5175-5181.
16. Biondi A, Schrappe M, De Lorenzo P, et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): A randomised, open-label, intergroup study. Lancet Oncol 2012; 13: 936-945.
17. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010; 115: 3206-3214.
18. Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009; 360: 470-480.
19. Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: A genome-wide classification study. Lancet Oncol 2009; 10: 125-134.
20. Roberts KG, Morin RD, Zhang J, et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 2012; 22: 153-166.
21. Ethier MC, Blanco E, Lehrnbecher T, et al. Lack of clarity in the definition of treatment-related mortality: Pediatric acute leukemia and adult acute promyelocytic leukemia as examples. Blood 2011; 118: 5080-5083.
22. Conter V, Arico M, Basso G, et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia 2010; 24: 255-264.
23. Escherich G, Horstmann MA, Zimmermann M, et al. Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): Long-term results of trials 82, 85, 89, 92 and 97. Leukemia 2010; 24: 298-308.
24. Gaynon PS, Angiolillo AL, Carroll WL, et al. Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: A children's oncology group report. Leukemia 2010; 24: 285-297.
25. Kamps WA, van der Pal-de Bruin KM, Veerman AJ, et al. Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004. Leukemia 2010; 24: 309-319.
26. Liang DC, Yang CP, Lin DT, et al. Long-term results of Taiwan Pediatric Oncology Group studies 1997 and 2002 for childhood acute lymphoblastic leukemia. Leukemia 2010; 24: 397-405.
27. Mitchell C, Richards S, Harrison CJ, et al. Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001. Leukemia 2010; 24: 416-418.
28. Moricke A, Zimmermann M, Reiter A, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 2010; 24: 265-284.
29. Salzer WL, Devidas M, Carroll WL, et al. Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: A report from the Children's Oncology Group. Leukemia 2010; 24: 355-370.
30. Schmiegelow K, Forestier E, Hellebostad M, et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia 2010; 24: 345-354.
31. Silverman LB, Stevenson KE, O'Brien JE, et al. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia 2010; 24: 320-334.
32. Stark B, Nirel R, Avrahami G, et al. Long-term results of the Israeli National Studies in childhood acute lymphoblastic leukemia: INS 84, 89 and 98. Leukemia 2010; 24: 419-424.
33. Stary J, Jabali Y, Trka J, et al. Long-term results of treatment of childhood acute lymphoblastic leukemia in the Czech Republic. Leukemia 2010; 24: 425-428.
34. Tsuchida M, Ohara A, Manabe A, et al. Long-term results of Tokyo Children's Cancer Study Group trials for childhood acute lymphoblastic leukemia, 1984-1999. Leukemia 2010; 24: 383-396.
35. Tsurusawa M, Shimomura Y, Asami K, et al. Long-term results of the Japanese Childhood Cancer and Leukemia Study Group studies 811, 841, 874 and 911 on childhood acute lymphoblastic leukemia. Leukemia 2010; 24: 335-344.
36. Bhojwani D, Pei D, Sandlund JT, et al. ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: Improved outcome with contemporary therapy. Leukemia 2012; 26: 265-270.
37. Matloub Y, Bostrom BC, Hunger SP, et al. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: A report for the Children's Oncology Group. Blood 2011; 118: 243-251.
38. Moorman AV, Ensor HM, Richards SM, et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: Results from the UK Medical Research Council ALL 97/99 randomised trial. Lancet Oncol 2010; 11: 429-438.
39. Ramakers-van Woerden NL, Pieters R, Loonen AH, et al. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood 2000; 96: 1094-1099.
40. Loh ML, Goldwasser MA, Silverman LB, et al. Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. Blood 2006; 107: 4508-4513.
41. Veerman AJ, Kamps WA, van den Berg H, et al. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: Results of the prospective Dutch Childhood Oncology Group (DCOG) Protocol ALL-9 (1997-2004). Lancet Oncol 2009; 10: 957-966.
42. Pui CH, Gaynon PS, Boyett JM, et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 2002; 359: 1909-1915.
43. Pui CH, Chessells JM, Camitta B, et al. Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia 2003; 17: 700-706.
44. Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukaemia: A subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009; 10: 147-156.
45. Zhang J, Ding L, Holmfeldt L, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012; 481: 157-163.
46. Downing J, Zhang J, Wilson RK, et al. The pediatric cancer genome project. Nat Genet 2012; 44: 619-622.
47. Homminga I, Pieters R, Langerak AW, et al. Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. Cancer Cell 2011; 19: 484-497.
48. Wood B, Winter S, Dunsmore KP, et al. Patients with early T-cell precursor (ETP) acute lymphoblastic leukemia (ALL) have high levels of minimal residual disease (MRD) at the end of induction-A Children's Oncology Group (COG) study. Blood 2009; 114: 9.
49. Mullighan CG, Collins-Underwood JR, Phillips LA, et al. Rearrangement of CRLF2 in B-progenitor- and down syndrome-associated acute lymphoblastic leukemia. Nat Genet 2009; 41: 1243-1246.
50. Mullighan CG, Zhang J, Harvey RC, et al. Jak mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2009; 106: 9414-9418.
51. Russell LJ, Capasso M, Vater I, et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 2009; 114: 2688-2698.
52. Baruchel A. Childhood all: Control it or not? Blood 2010; 117: 2081-2082.
53. Cario G, Zimmermann M, Romey R, et al. Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood 2010; 115: 5393-5397.
54. Harvey RC, Mullighan CG, Chen IM, et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, hispanic/latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 2010; 115: 5312-5321.
55. Hertzberg L, Vendramini E, Ganmore I, et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: A report from the International BFM Study Group. Blood 2010; 115: 1006-1017.
56. Yoda A, Yoda Y, Chiaretti S, et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2010; 107: 252-257.
57. Ensor HM, Schwab C, Russell LJ, et al. Demographic, clinical and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: Results from the MRC ALL97 clinical trial. Blood 2011; 117: 2129-2136.
58. Chen IM, Harvey RC, Mullighan CG, et al. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: A Children's Oncology Group study. Blood 2012; 119: 3512-3522.
59. Palmi C, Vendramini E, Silvestri D, et al. Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. Leukemia 2012; DOI: 10.1038/leu.2012.101 [Epub ahead of print].
60. Pieters R, Hunger SP, Boos J, et al. L-asparaginase treatment in acute lymphoblastic leukemia: A focus on Erwinia asparaginase Cancer 2011; 117: 238-249.
61. Arico M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000; 342: 998-1006.
62. Heerema NA, Harbott J, Galimberti S, et al. Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome. Leukemia 2004; 18: 693-702.
63. Moorman AV, Raimondi SC, Pui CH, et al. No prognostic effect of additional chromosomal abnormalities in children with acute lymphoblastic leukemia and 11q23 abnormalities. Leukemia 2005; 19: 557-563.
64. Nachman JB, Heerema NA, Sather H, et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 2007; 110: 1112-1115.